SHAH ALAM, 26 August 2025 – Pharmaniaga Berhad (Pharmaniaga or the Group) continued to build momentum in the second quarter of the financial year ended 30 June 2025 (Q2 FY2025), delivering stronger earnings across its pharmaceutical, manufacturing, and logistics segments while reinforcing its turnaround strategy.
The Group reported a Profit After Taxation (PAT) of RM4.2 million, a 9.5% year-on-year increase from RM3.8 million in Q2 FY2024. Revenue rose 10.6% to RM926.9 million, supported mainly by higher concession orders from government hospitals and the inclusion of new products under the Approved Products Purchase List (APPL). Earnings before interest, taxation, depreciation, and amortisation (EBITDA) also improved 9.2% to RM34.2 million, reflecting stronger operational performance.
First-Half Performance
For the first half of FY2025 (1H FY2025), Pharmaniaga recorded RM2.0 billion in revenue, up 9.9% year-on-year. EBITDA climbed to RM106.3 million from RM97.8 million, while Profit Before Zakat and Taxation (PBT) increased to RM52.9 million from RM42.4 million.
The Group manufactured 86 in-house products under Ministry of Health (MOH) contracts during the period, covering cardiovascular, metabolic, and anti-infective therapeutic areas. Alongside this, cost optimisation and effective inventory management delivered RM1.7 million in operating expense savings and RM1.0 million in interest savings.
Divisional Highlights
- Manufacturing Division: EBITDA surged to RM50.3 million compared with RM31.6 million in the same period last year, driven by stronger hospital demand. The division contributed more than 80% of the Group’s net profit, reinforcing its role as the primary earnings driver.
- Logistics & Distribution: EBITDA moderated to RM37.2 million from RM45.9 million, weighed by higher cost of goods sold under the new concession agreement. However, higher volumes from government hospitals and expanded APPL product listings helped cushion the decline.
- Indonesia Operations: Revenue grew 1% (in IDR), led by higher in-house product sales. EBITDA eased to RM17.4 million from RM19.8 million due to increased marketing investments and currency fluctuations. The Group expects promotional efforts to bolster long-term growth.
Strategic Progress and Outlook
Pharmaniaga Managing Director Dato’ Zulkifli Jafar expressed confidence in the Group’s recovery trajectory:
“We are pleased to sustain our positive momentum into the second quarter, with our Manufacturing Division continuing to drive profitability. This performance underlines our progress towards exiting PN17 status.”
The Group also highlighted advances in its biopharmaceutical segment, with additional tenders secured for its human insulin programme and nine process validation batches completed in May 2025. Registration is targeted by year-end.
Two new pharmaceutical products were launched in the anti-infectives and urology segments, while in Indonesia, Pharmaniaga is set to open its 37th branch in Palu, Sulawesi by Q4 FY2025.
Earlier this month, Pharmaniaga achieved a major milestone by completing its Regularisation Plan, including a Rights Issue, Private Placement, and Capital Reduction. This restored compliance with Bursa Malaysia’s Main Market Listing Requirements, positioning the Group to exit PN17 by Q1 2026.
“This marks a significant turning point for Pharmaniaga. With stronger financial footing, expanded product offerings, and continued support from stakeholders, we are confident in building a more resilient and future-ready Group,” Zulkifli added.
